


**Statement of Standalone Unaudited Financial Results for the Quarter & Nine months Ended on 31/12/2015**

PART-I							
(Rs. in Lacs except per share data) (Rs. In Lacs)							
Sr. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Year to date figures for the previous year ended	Previous year ended
		31/12/2015	30/09/2015	31/12/2014	31/12/2015	31/12/2014	31/03/2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
(a)	Net Sales/Income from Operations (Net of excise	2406.10	2512.57	2133.92	7102.98	6277.25	8501.80
(b)	Other Operating Income	14.36	5.25	4.31	57.35	7.98	19.24
	<b>Total income from Operations (net)</b>	<b>2420.46</b>	<b>2517.82</b>	<b>2138.23</b>	<b>7160.33</b>	<b>6285.23</b>	<b>8521.04</b>
2	<b>Expenses</b>						
(a)	Cost of Materials Consumed	201.43	180.92	187.41	556.30	530.18	747.82
(b)	Purchase of Stock-in-trade	556.94	712.71	497.90	1754.11	1465.01	1910.60
(c)	Changes in inventories of Finished Goods, Work-in Progress and Stock-in-trade	-55.18	-116.62	-39.39	-163.51	-83.08	-65.26
(d)	Employee benefit expenses	533.43	509.33	488.61	1591.75	1431.69	1899.32
(e)	Depreciation and Amortisation Expense	51.87	46.73	68.34	144.35	188.34	265.90
(f)	Other expenses	694.70	706.46	584.40	2046.53	1818.55	2503.24
	<b>Total Expenses</b>	<b>1983.19</b>	<b>2039.53</b>	<b>1787.27</b>	<b>5929.53</b>	<b>5350.69</b>	<b>7261.62</b>
3	Profit from operations before other income, finance costs and exceptional items (1-2)	437.27	478.29	350.96	1230.80	934.54	1259.42
4	Other income	67.23	59.54	18.28	185.67	49.05	207.24
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	504.50	537.83	369.24	1416.47	983.59	1466.66
6	Finance Costs	8.01	7.34	10.22	25.74	26.41	35.65
7	Profit from ordinary activities after finance costs but before exceptional items (5 + 6)	496.49	530.49	359.02	1390.73	957.18	1431.01
8	Exceptional Items	-0.10	0.10	0.00	0.00	0.16	2.98
9	Profit from ordinary activities before tax (7 + 8)	496.39	530.59	359.02	1390.73	957.34	1433.99
10	Tax Expense	146.14	187.66	57.48	442.20	216.23	469.08
11	Net Profit from ordinary activities after tax (9 + 10)	350.25	342.93	301.54	948.53	741.11	964.91
12	Extraordinary items (net of tax ` expense ____ Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11 + 12)	350.25	342.93	301.54	948.53	741.11	964.91
14	Paid-up equity share capital - F.V. Rs. 10/-	464.93	464.93	464.93	464.93	464.93	464.93
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	2878.94
16	(i) Earnings Per Share (before extraordinary items)						
	Basic and diluted	7.53	7.38	6.49	20.40	15.94	20.75
	(ii) Earnings Per Share (after extraordinary items)						
	Basic and diluted	7.53	7.38	6.49	20.40	15.94	20.75

Place : Mumbai  
Date : 11/02/2016.

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.

  
(Ashish U. Bhuta)  
Chairman and Managing Director.

 Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai





**Dilip. L. Arora**

**B.Com (Hons.), F.C.A**

**D.L.ARORA & Co.**  
**CHARTERED ACCOUNTANTS**

**LIMITED REVIEW REPORT TO THE BOARD OF DIRECTORS OF JENBURKT  
PHARMACEUTICALS LIMITED**

TO  
THE BOARD OF DIRECTORS,  
JENBURKT PHARMACEUTICALS LIMITED,  
Mumbai

We have reviewed the accompanying statement of unaudited statement of financial result of **Jenburkt Pharmaceuticals Limited** ("the company") for the quarter/ period ended on December 31, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors on 11<sup>th</sup> February, 2016. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of Interim Financial Information consist of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards prescribed by section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai.

Date: 11<sup>th</sup> February, 2016.

E:\My Documents - 1\Jenburkt\JPL 15-16\Limited review report.



For D.L.Arora & Co.  
Chartered Accountants  
FRN.: 100545W

*AK*  
Dilip Arora  
Proprietor  
M. No.: 036152